Scientific Poster - Reducing Misdiagnosis of Alzheimer’s Disease Pathology Utilizing CSF and Amyloid PET
Background
Utilizingcognitivetestsalone,includingtheMini-MentalStateExamination(MMSE)ortheMontrealCognitiveAssessment(MoCA),cannotdetectthepresenceofamyloidplaquesandtanglesinAlzheimer’sdisease(AD).WhileinlatestagesofAD,clinicaldiagnosisrelyingprimarilyoncognitivetestingiscorrect70-90%ofthetime,inmildcognitiveimpairment(MCI)accuracyisreducedto50-60%1,2.AlthoughautopsyisthegoldstandardforADdiagnosis,amyloidPETimagingandmorerecentlytheLumipulseGβ-AmyloidRatio(1-42/1-40)arevalidatedtodetermineamyloidpathology.WiththeupcomingavailabilityofdiseasemodifyingtherapiestargetingamyloidinMCIandearlyAD,andanti-taudrugsinthepipeline,itisnecessarytohavetruemeasuresofADpathologyforaclinicalevaluationearlyinthediseaseprocess.HereweexaminetheperformanceofcognitivetestingaloneforidentificationofamyloidpositivityinMCIpatientsfromtheADNIstudywhencomparedtoamyloidPETandCSFtesting.
Related articles
Video - A Neurochemist's Search to Save Memories - Christa's and Charlotte's Story About Alzheimer's Disease
Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, who was diagnosed with Alzheimer's disease in...
Scientific Poster - In an Optimized CSF Collection Protocol the pTau181/Aβ1-42 Ratio Increases Preanalytical Variability Over Measuring Aβ1-42 Alone
Background
Core cerebrospinal fluid (CSF) biomarker concentrations for β-amyloid1-42 (Aβ1-
42), β-amyloid1-40 (Aβ1-40), and pTau181 are valuable in...
Scientific Poster - Pre-analytics of the Aβ1-42/Aβ1-40 Ratio in Fresh and Frozen Samples Using an Optimized CSF Collection Protocol
Background
Cerebrospinal fluid (CSF) biomarkers β-amyloid1-42 (Aβ1-42) and β-amyloid1-40 (Aβ1-40)
have shown high concordance with amyloid PET when...
Scientific Poster - A fully Automated Method That Combines CSF Concentrations of Lumipulse G β-Amyloid 1-42 and 1-40 Into a Numerical Ratio
Study Objective
The aim of this study was to analytically verify the Lumipulse G
β-Amyloid Ratio (1-42/1-40) assay and evaluate performance of
the...
Scientific Poster - Prediction of Amyloid PET Status Using the Lumipulse G β Amyloid Ratio (1-42/1-40)
Background
Cerebrospinal fluid ( amyloid biomarker concentrations are valuable
in the assessment of patients for Alzheimer’s dementia ( Automated...
Scientific Poster - Clinical Validation of the Lumipulse® G β-Amyloid Ratio (1-42/1-40) in a Subset of ADNI CSF Samples
Background
The CSF Lumipulse G β-Amyloid Ratio (1-42/1-40)1 provides a potential
alternative to amyloid PET testing for patients with cognitive...
The evolution of Alzheimer's disease diagnosis
By Rianne Esquivel, PhD and Francesca I. De Simone, PhD
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and is...
Comparison of Aβ1-42/Aβ1-40 ratio with other ratios
CSF Aβ1-42/Aβ1-40 is a tool thought to normalize atypical amyloid levels, whereas other ratios might be seen more as interpretation tools that allow...
The role of Aβ1- 40 in the Aβ1-42/Aβ1- 40 ratio
Aβ1-40 is the most abundant amyloid peptide in CSF, while Aβ1-42 accounts for only about 10% of the total Aβ peptide population.15 Total Aβ...
Aβ1-42/Aβ1-40 ratio to decrease preanalytical variability
- Aβ1-42 adsorption to plastic is a relevant preanalytical factor in laboratory practice.
- Adsorption to plastic seems to affect different Aβ isoforms...
Association between the CSF Aβ1- 42/Aβ1-40 ratio and amyloid PET
Most studies have found a strong association between CSF Aβ1-42 and amyloid PET measurements. However, in these studies, 10–20% of healthy individuals...
Understanding the Aβ1-42/Aβ1-40 ratio in relation to Alzheimer’s Disease
CSF Aβ1-42/Aβ1-40 ratio as a potential tool to detect amyloid deposition
